GORAB

GORAB is a trans-Golgi golgin that scaffolds COPI-mediated retrograde transport and is required for normal protein glycosylation, with its loss causing the progeroid skin-and-bone disorder gerodermia osteodysplastica (PMID:18997784, PMID:30631079). It associates loosely with trans-Golgi membranes—being rapidly displaced by Brefeldin A—through an internal IGRAB domain that binds both the small GTPase RAB6 and the GTP-bound active form of ARF5 (PMID:18997784, PMID:26000619). At the trans-Golgi, GORAB assembles into stable membrane domains that, via interaction with the COPI-binding protein SCYL1, recruit COPI to enable retrieval of trans-Golgi glycosylation enzymes; loss of GORAB impairs this retrieval and produces deficient glycosylation of secretory cargo (PMID:30631079). Pathogenic missense mutations map to the IGRAB domain and disrupt this machinery: p.Ala220Pro mislocalizes GORAB to the cytoplasm and abolishes both RAB6 and ARF5 binding, while p.Ser175Phe displaces it to vesicular structures and selectively impairs ARF5 binding (PMID:26000619), and other mutations perturb SCYL1 binding or domain assembly (PMID:30631079). In vivo, conditional deletion of Gorab in long bones recapitulates skeletal aging, with reduced cortical bone, delayed mineralization, and diminished whole-bone strength, establishing GORAB as required for bone integrity (PMID:29108851). Separately, GORAB has been reported to act in a nuclear MDM2/p53 axis—stabilizing p53 by suppressing MDM2-mediated ubiquitination (PMID:20849854) and inhibiting neurite outgrowth and axonal regeneration by inducing Mdm2 transcription to lower p53 levels (PMID:23051735)—a role less integrated with its Golgi function.

1. 2008 High

   Established GORAB's identity and disease relevance by showing it is a Golgi-localized RAB6-binding golgin whose loss causes gerodermia osteodysplastica, defining the secretory pathway as the disease mechanism.

   Evidence Patient mutation identification with subcellular localization and protein interaction assays

   PMID:18997784

   Open questions at the time

   • Did not define the membrane-targeting domain or the molecular consequence of RAB6 binding
   • No link yet to a downstream transport step or cargo
2. 2009 Low

   Confirmed loss-of-function as the pathogenic mechanism by showing a missense mutation produces a null-equivalent phenotype in gerodermia osteodysplastica families.

   Evidence Homozygosity mapping and linkage analysis in Saudi families

   PMID:19681135

   Open questions at the time

   • Genetic mapping only, no direct functional assay of the missense allele
   • Does not extend the molecular model
3. 2010 Medium

   Proposed a nuclear function by showing GORAB overexpression stabilizes p53 through suppression of MDM2-specific ubiquitination, coupling it to growth arrest and apoptosis.

   Evidence Ubiquitination assays with MDM2 specificity control, transcriptional reporters, proliferation/apoptosis/tumorigenicity assays

   PMID:20849854

   Open questions at the time

   • Relies on overexpression; endogenous relevance unestablished
   • Mechanism of MDM2 inhibition not resolved
   • Not reconciled with the Golgi localization established earlier
4. 2012 Medium

   Extended the p53 connection to neuronal biology by showing GORAB represses neurite outgrowth and axonal regeneration via transcriptional induction of Mdm2 and consequent p53 degradation.

   Evidence Overexpression/shRNA in PC12 cells and primary neurons, neurite assays, Mdm2 promoter assay, siRNA epistasis, in vivo regeneration model

   PMID:23051735

   Open questions at the time

   • Direction of p53 effect (degradation here vs. stabilization in 2010) not reconciled
   • Transcriptional activator role not biochemically defined
   • Mdm2 siRNA rescue only partial
5. 2015 High

   Defined the membrane-targeting mechanism by mapping an IGRAB domain that binds RAB6 and active ARF5, and tied two disease mutations to specific binding/localization defects.

   Evidence Yeast two-hybrid, fluorescence microscopy, Brefeldin A displacement, site-directed mutagenesis of pathogenic mutations

   PMID:26000619

   Open questions at the time

   • Did not establish the downstream transport step served by RAB6/ARF5 binding
   • Functional role of ARF5 vs RAB6 binding distinct contributions unresolved
6. 2017 Medium

   Demonstrated a tissue-level in vivo requirement by showing conditional Gorab deletion in long bones recapitulates skeletal aging with reduced mineralization and bone strength.

   Evidence Cre-lox conditional knockout with microCT, FTIR, strain gauge, finite element analysis, three-point bending

   PMID:29108851

   Open questions at the time

   • Molecular pathway connecting Golgi/glycosylation defect to bone phenotype not resolved
   • Cell-type-specific mechanism in osteoblasts not defined
7. 2019 High

   Provided the unifying molecular function: GORAB forms stable trans-Golgi domains that recruit COPI via SCYL1 to enable retrieval of glycosylation enzymes, explaining the glycosylation defect underlying disease.

   Evidence Co-immunoprecipitation, GORAB knockout/knockdown, COPI recruitment and glycosylation assays, pathogenic mutation analysis

   PMID:30631079

   Open questions at the time

   • Specific enzymes whose retrieval depends on GORAB not exhaustively identified
   • Structural basis of domain assembly unresolved
   • Relationship between Golgi function and the MDM2/p53 axis not established

• How the trans-Golgi COPI-scaffolding function relates mechanistically to the reported nuclear MDM2/p53 activity, and how either pathway causes the skin and bone pathology, remains unresolved.
• No experiment links Golgi/glycosylation function to p53 regulation
• Causal chain from glycosylation defect to gerodermia osteodysplastica phenotype not defined